Delving into the Latest Updates on RHYK2001 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Hyperparathyroidism, Secondary

Originator Organization

Renhe Yikang Group Co., Ltd.

Active Organization-

Inactive Organization

Renhe Yikang Group Co., Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

主要试验目的：在健康受试者体内，分别在空腹和餐后条件下，以日本协和发酵麒麟株式会社持有的盐酸西那卡塞片（商品名：REGPARA®；规格：25 mg）为对照药，研究仁合益康集团有限公司持有的RHYK2001（规格：25 mg/10 mL（30mL）；试验药）的药代动力学，为后期临床试验提供基础和依据。次要试验目的：观察试验药和对照药在健康受试者中的安全性

[Translation]

The main purpose of the study: In healthy subjects, under fasting and postprandial conditions, using Cinacalcet Hydrochloride Tablets (trade name: REGPARA®; specification: 25 mg) owned by Kyowa Hakko Kirin Co., Ltd. as the control drug, to study the pharmacokinetics of RHYK2001 (specification: 25 mg/10 mL (30 mL); experimental drug) owned by Renhe Yikang Group Co., Ltd., to provide a basis and basis for later clinical trials. Secondary purpose of the study: To observe the safety of the experimental drug and the control drug in healthy subjects

Start Date17 Jul 2022

Sponsor / Collaborator

Renhe Yikang Group Co., Ltd.

100 Clinical Results associated with RHYK2001

Login to view more data

100 Translational Medicine associated with RHYK2001

Login to view more data

100 Patents (Medical) associated with RHYK2001

Login to view more data

100 Deals associated with RHYK2001

Login to view more data